Article

Balstilimab Monotherapy or Plus Zalifrelimab Active in Recurrent/Metastatic Cervical Cancer

Author(s):

The investigative PD-1 inhibitor balstilimab as a single agent and combined with the CTLA-4 inhibitor zalifrelimab showed promising objective response rates, regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent/metastatic cervical cancer.

David O’Malley, MD

The investigative PD-1 inhibitor balstilimab as a single agent and combined with the CTLA-4 inhibitor zalifrelimab showed promising objective response rates (ORRs), regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent/metastatic cervical cancer, according to findings of 2 independent phase 2 trials presented during the 2020 ESMO Virtual Congress.1

In the modified intent-to-treat (ITT) population, single-agent balstilimab elicited a 14% ORR, which included 3 complete responses (CRs) and 20 partial responses (PRs); when explored in combination with zalifrelimab, the ORR increased to 22%, with 8 CRs and 23 PRs. Additionally, the median duration of response (DOR) was 15.4 months (1.1+ to 15.4) with balstilimab monotherapy and was not reached (1.3+ to 16.6+) when used in combination.

“This is, by far, the largest reported study of checkpoint inhibitors in [patients with] recurrent/metastatic cervical cancer reported to date. We demonstrated responses in both PD-L1–positive and PD-L1–negative tumors in patients treated with single-agent balstilimab and with the combination of balstilimab/zalifrelimab,” lead investigator David O’Malley, MD, professor of obstetrics and gynecology at The Ohio State University College of Medicine, said in a virtual presentation during the meeting. “These results demonstrate that both single-agent balstilimab and the balstilimab/zalifrelimab combination are effective and well tolerated in the second-line treatment of [patients with] recurrent/metastatic cervical cancer.”

The presentation follows a September 2020 announcement from the manufacturer of balstilimab, Agenus Inc., which stated that a rolling submission of a biologics license application to the FDA has been initiated for single-agent balstilimab for the treatment of patients with recurrent/metastatic cervical cancer.2

One of the phase 2 trials, both of which were parallel, single-arm studies, evaluated single-agent balstilimab at 3 mg/kg every 2 weeks (NCT03104699), while the second explored the PD-1 inhibitor at the same dosage in combination with zalifrelimab at a dose of 1 mg/kg every 6 weeks (NCT03495882), both in patients with recurrent/metastatic cervical cancer. Imaging was conducted every 6 weeks for 2 years.

To be eligible for enrollment, patients must have had histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix that had relapsed following platinum-based therapy, measurable baseline disease, and an ECOG performance status of 0 or 1.

The primary end point of the trial was ORR via RECIST v1.1 criteria, as assessed by an independent review committee; secondary end points were progression-free survival, overall survival, DOR, and safety. PD-L1 positivity was defined as a combined positive score (CPS) of 1% or higher.

In the single-agent trial, 161 patients comprised the safety population, and 160 were in the modified ITT population; 138 patients had received 1 or more prior line of chemotherapy. The median age was 53 years, and 47% of patients had an ECOG performance status of 0. A total 62% of patients had a CPS of 1% or higher, 63% had squamous cell histology, and 37% had adenocarcinoma/adenosquamous histology.

In the combination trial, 155 patients were in the safety population, and 119 had received 1 or more lines of chemotherapy. A total 143 patients comprising the modified ITT population with baseline measurable disease. The median age was 50 years, and 57% of patients had an ECOG performance status of 0. Fifty-five percent of patients had a CPS of 1% or higher, and 70% had squamous histology. Thirty percent of patients had adenocarcinoma/adenosquamous histology.

In patients who received 1 or more lines of prior chemotherapy, the ORR in the single-agent balstilimab trial was 13%, with 3 CRs and 15 PRs. For those who received the combination and prior chemotherapy, the ORR was 20%, with 6 CRs and 18 PRs.

When stratified by histology, the ORR was higher in patients with squamous cell carcinoma who received the combination (27%) versus the single agent (18%), suggesting a predictor of response, O’Malley explained. For the adenocarcinoma/adenosquamous/other histology, the ORRs were 8% for those on single-agent balstilimab and 5% for patients on the combination.

Moreover, on the monotherapy study, the ORRs were 19%, 10%, and 0% for those with PD-L1–positive disease, PD-L1–negative disease, and unknown PD-L1 status, respectively. In the combination study, these rates were 27%, 11%, and 21%, respectively.

Regarding safety, the treatment was found to be well tolerated in both studies and no new safety signals were identified, with all-grade endocrine disorders more common with the combination compared with single-agent balstilimab (20.6% vs 9.3%, respectively).

The combination trial also saw more immune-related adverse effects (irAEs) than the single-agent study, O’Malley noted. Specifically, gastrointestinal (GI) disorders occurred in 8.4% and 5.6% of the combination and monotherapy arms, respectively, as well as laboratory abnormalities (11.6% vs 5.6%) and endocrine disorders (18.7% vs 5.0%). Grade 3 or higher immune-related treatment-related adverse effects were GI disorders (2.6% with the combination vs 3.1% with balstilimab alone), laboratory abnormalities (3.9% vs 1.2%, respectively), and skin and subcutaneous tissue disorders (1.9% vs 0.6%).

“Given the limited treatments available for our patients with recurrent/metastatic cervical cancer, both single-agent balstilimab and the combination of balstilimab/zalifrelimab present important treatment options for our patients,” O’Malley concluded.

References:

  1. O’Malley DM, Oaknin A, Monk B, et al. Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials. Presented at: 2020 ESMO Congress; September 19-21, 2020; virtual. Abstract LBA34.
  2. Agenus initiates rolling BLA submission of balstilimab for recurrent/metastatic cervical cancer. News release. Agenus Inc. September 18, 2020. Accessed September 18, 2020. https://bit.ly/35OGfVH.
Related Videos
FRCSI, FRCSEd, medical director, Thoracic Cancer Program, and associate executive director, AdventHealth Cancer Institute
Benjamin P. Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor, oncology, Johns Hopkins University School of Medicine
Russell Hales, MD, director, Thoracic Oncology Multidisciplinary Program, associate professor, clinical radiation oncology and molecular radiation sciences, and director, thoracic multidisciplinary clinic, John Hopkins University School of Medicine
Estelamari Rodriguez, MD, MPH, associate director, Community Outreach – Thoracic Oncology, Sylvester Comprehensive Cancer Center
Kathleen N. Moore, MD, MS
Dana M. Chase, MD
Misty D. Shields, MD, PhD, assistant professor, clinical medicine, Department of Medicine, Division of Hematology/Oncology, Indiana University (IU) School of Medicine; and associate member, Experimental and Developmental Therapeutics, IU Melvin and Bren Simon Comprehensive Cancer Center
Corey J. Langer, MD, director, Thoracic Oncology, Penn Medicine; and professor, medicine (hematology-oncology), the Hospital of the University of Pennsylvania, Perelman School of Medicine
R. Wendel Naumann, MD, professor and director of gynecologic oncology research, and associate medical director of clinical trials, Levine Cancer Institute, Atrium Health
Stéphanie Lheureux, MD, PhD, clinician investigator, Cancer Clinical Research Unit, Princess Margaret Cancer Centre